Management algorithm for AML with NPM1 mutations according to MRD. ∗In this study, no difference in overall survival was observed between myeloablative and reduced-intensity conditioning. ∗∗With current induction and consolidation therapy combining IC and FLT3-i, around 50% of relapses are FLT3-wild type, and therefore, using a FLT3-i in molecular relapse or posttransplant is still uncertain clinically. AZA-VEN, azacitidine-venetoclax; Dx, diagnosis; -i, inhibitors; IC, intensive chemotherapy; PB, peripheral blood.